Brentuximab vedotin improves outcomes

Around 80% of children and young adults with advanced-stage high-risk Hodgkin lymphoma have durable responses to chemotherapy; however, this approach can be associated with late-onset toxicities. Furthermore, the remaining ~20% of patients will require treatment intensification. Now, data from a phase III trial demonstrate the potential of brentuximab vedotin to improve efficacy.

留言 (0)

沒有登入
gif